EGRIFTA SV™ and COVID-19 Pandemic. Read More. ×

EGRIFTA SV™ is an injectable prescription medicine used to reduce excess abdominal fat in adult patients living with HIV and lipodystrophy.

Download Doctor
Discussion Guide Download Doctor
Discussion Guide

Call THERA patient support^® - 1-833-23THERA (1-833-238-4372) - MON-FRI 8:30 a.m.-8 p.m. ET

Find a specialist

Find a specialist

EGRIFTA SV™
reduces HARD BELLY
(excess visceral abdominal fat)

Ask your healthcare provider if
EGRIFTA SV™ may be right for you

What is “HARD BELLY”?

HARd BELLY is a buildup of extra hard fat in the abdominal (belly) area. HARD BELLY is different from regular fat.

Find out about HARD BELLY

EGRIFTA SV™ is an FDA approved treatment* used to reduce excess abdominal fat.

It has been proven to significantly reduce HARD BELLY (excess visceral abdominal fat).

Learn more

THERA patient support^® provides personal service to help you make the most of therapy.

The Staff Nurses and Patient Care Coordinators are your go-to resources for everyday support.

See the benefits

EGRIFTA SV™ is not approved to reduce the health consequences of HARD BELLY (excess visceral abdominal fat).

*An approved strength of tesamorelin for injection with the same efficacy and safety of tesamorelin 1 mg/vial. The 2 mg/vial is more concentrated than the 1 mg/vial, and the recommended daily dose is 1.4 mg.